Pathogenic role of IL-17 in psoriasis and psoriatic arthritis

Actas Dermosifiliogr. 2014 Oct:105 Suppl 1:9-20. doi: 10.1016/S0001-7310(14)70014-6.

Abstract

Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics. Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis.

Keywords: Arthritis; Artritis; Aterosclerosis; Atherosclerosis; Brodalumab; IL-17; Ixekizumab; Obesidad; Obesity; Psoriasis; Secukinumab.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Arthritis, Psoriatic / drug therapy
  • Arthritis, Psoriatic / etiology
  • Arthritis, Psoriatic / immunology
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Disease Susceptibility
  • Double-Blind Method
  • Humans
  • Infections / etiology
  • Inflammation / immunology
  • Interleukin-17 / antagonists & inhibitors
  • Interleukin-17 / physiology*
  • Interleukin-23 / immunology
  • Mice
  • Models, Immunological
  • Neoplasms / etiology
  • Psoriasis / drug therapy
  • Psoriasis / etiology*
  • Psoriasis / immunology
  • Randomized Controlled Trials as Topic
  • Receptors, Interleukin-17 / antagonists & inhibitors
  • Receptors, Interleukin-17 / physiology
  • T-Lymphocyte Subsets / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Interleukin-17
  • Interleukin-23
  • Receptors, Interleukin-17
  • brodalumab
  • ixekizumab
  • secukinumab